Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. San Diego Compounding Pharmacy
WARNING LETTER
•San Diego Compounding Pharmacy•November 15, 2016

San Diego Compounding Pharmacy – FDA Warning Letter, Nov 15, 2016

Record Details

The FDA issued a Warning Letter to San Diego Compounding Pharmacy, P.C. following an inspection from October 17 to November 15, 2016. The inspection revealed that drug products produced by the firm failed to meet the conditions of section 503A of the FDCA, specifically by not receiving valid prescriptions for individually-identified patients. This renders these products ineligible for exemptions from CGMP, adequate directions for use, and FDA approval requirements.

Furthermore, the FDA investigator noted serious deficiencies in sterile drug production. Drug products intended to be sterile were prepared under insanitary conditions, making them adulterated under section 501(a)(2)(A) of the FDCA, exemplified by a failure to measure pressure differentials. Significant CGMP violations were also observed, causing ineligible drug products to be adulterated under section 501(a)(2)(B) of the FDCA. These included failure to establish and follow written procedures to prevent microbiological contamination and validate aseptic processes (21 CFR 211.113(b)), and failure to establish an adequate environmental monitoring system (21 CFR 211.42(c)(10)(iv)). Additionally, ineligible drug products were misbranded under section 502(f)(1) of the FDCA due to inadequate directions for use.

The firm responded by stating it would not renew its Licensed Sterile Compounding (LSC) License. The FDA recommends a comprehensive assessment, potentially with a third-party consultant, if the firm decides to resume sterile drug production. The firm must notify the FDA within 15 working days of corrective actions or intent not to resume sterile production, and 15 days prior to any future resumption of sterile drug production. Failure to correct violations may result in legal action.

Company
San Diego Compounding Pharmacy
Inspection date
November 15, 2016
Product type
Drugs
Office
Los Angeles District Office
People
  • Jessica Mu (Ms.)
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 66456cfb-1391-4ee9-875b-29a6c2a924bf

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 351(a)(2)(A)21 U.S.C. 301(k)21 CFR 211.113(b)21 CFR 211.42(c)(10)(iv)21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for San Diego Compounding Pharmacy
  • STATE_REFERRAL_LETTER - 2018-10-17October 17, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore San Diego Compounding Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.